Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T15:47:14.421Z.
Consensus retrieved: 2026-10-06T13:16:35.122Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T15:47:14.421Z.
Quote observation: 2026-10-06T15:39:37.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b407bf9ab9426f7f8731c51b1e955f2cfcbe23f9f3e819a9868889fb687bb4da
Forward PE Ratio (N/A) = Dated Quote Price ($0.45) / Consensus Forward EPS ($-0.76)
FORWARD PE RATIO
N/A
Pasithea Therapeutics Corp.
Market Cap
$15.03M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Pasithea Therapeutics Corp. (KTTA) | $15.03M | N/A |
| Karyopharm Therapeutics Inc. (KPTI)vs › | $15.06M | N/A |
| Cocrystal Pharma, Inc. (COCP)vs › | $15.58M | N/A |
| Obsidian Therapeutics Inc. (OBX)vs › | $14.37M | N/A |
| Pulsenmore Ltd. Ordinary Shares (PLSM)vs › | $14.37M | N/A |
| Allarity Therapeutics, Inc. (ALLR)vs › | $15.83M | N/A |
| BioCardia, Inc. (BCDA)vs › | $16.08M | N/A |
| Vyome Holdings, Inc. (HIND)vs › | $13.97M | N/A |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $13.90M | N/A |
| IN8bio, Inc. (INAB)vs › | $13.81M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $0.45, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.76 | $-0.76 – $-0.76 | 1 | n/m |
| 2027-12-31 | $-0.46 | $-0.46 – $-0.46 | 1 | n/m |
| 2028-12-31 | $-0.55 | $-0.55 – $-0.55 | 1 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
